Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...
Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from...
Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study
China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient...
ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion
Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review
China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...
Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...
Ascletis Pharma Files IND Application for ASC10 with US FDA
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...
MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...
Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...
Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion
China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...
Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...
Wuxi Biologics Set to Be Removed from US Restricted Trade List
Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...
CDE Releases 60th Batch of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...
Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies
China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...
Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development
China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...
Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM
China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...
Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...